相关实验视频

Updated: Sep 15, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

干扰ARID1B招募到核孔综合体作为一种新的抗癌治疗策略

Olena Odnokoz^1,2, Anupam Banerjee³, Xin Cui^1,2

¹Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, 30322, USA.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|July 17, 2025

概括

ARID1B核进口燃料三阴性乳腺癌 (TNBC) 的增长和耐药性. 阻止这种转移为TNBC提供了一种新的治疗策略,提高了治疗效率.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症遗传学癌症遗传学

背景情况:

三阴性乳腺癌 (TNBC) 是一种具有攻击性的亚型,缺乏有效的向疗法.
ARID1B是一种SWI/SNF复合体子单元,涉及高度恶性瘤和不良预后.
癌症中ARID1B的确切功能和调节在很大程度上是未知的.

研究的目的:

阐明ARID1B核进口在TNBC瘤发生和耐药性中的作用.
确定控制ARID1B核转位的分子机制.
评估抑制TNBC中ARID1B核进口的治疗潜力.

主要方法:

蛋白质复合体净化和质谱测量以确定ARID1B相互作用伙伴.
局部定向的突变发生来破坏ARID1B蛋白相互作用.
关键核进口因素的药理抑制.
ARID1B淘汰赛小鼠模型和使用PARP抑制剂的疗效研究.

主要成果:

不受控制的ARID1B积累和核进口促进TNBC瘤发生和耐药性.
ARID1B对ARID1A进行负面调节,减少SWI/SNF瘤抑制活性.
KPNA2-KPNB1-RANBP2级联被确定为ARID1B核进口的关键.
特定的ARID1B残留突变和KPNB1抑制阻断ARID1B的核转位.
ARID1B淘汰会减少瘤生长,并使TNBC对PARP抑制剂产生敏感性.

结论:

ARID1B核转位是TNBC中一个关键的瘤驱动因素.
通过KPNB1抑制或特定突变准ARID1B核进口,代表了一个新的治疗途径.
阻止ARID1B核转移可以克服耐药性并改善TNBC治疗结果.

关键词:

在 ARID1B 里面,你会看到 ARID1B.KPNA2 KPNA2 的意思是什么?在KPNB1中使用.这就是RANBP2的原因.癌症发生的原因是癌症发生.核转移的转移是核转移的转移.

更多相关视频

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Drugs that Destabilize Microtubules

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...